CIK 0001341235 · Non-accelerated filer<br>Smaller reporting company
Aldeyra Therapeutics, Inc.
Sign in to watch- Ticker
- ALDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-761-4904
- Business address
- 23 BRADFORD STREET, SUITE 1, CONCORD, MA, 01742
- Former names
- Aldexa Therapeutics, Inc., Neuron Systems Inc
- 4 Open-market buy 10% owner bought 141,000 shares at $6.95 ($979,950)
- 4 Open-market buy 10% owner bought 95,100 shares at $6.17 ($586,767)
- 4 Open-market buy 10% owner bought 100,000 shares at $5.84 ($584,000)
- 4 Open-market buy 10% owner bought 412,406 shares at $5.59 ($2,305,350)
- 4 Open-market buy 10% owner bought 144,185 shares at $5.05 ($728,134)
- 4 Open-market buy 10% owner bought 222,123 shares at $5.03 ($1,117,279)
- 4 Open-market buy 10% owner bought 119,392 shares at $5.00 ($596,960)
- 4 Derivatives Options or other derivatives
- 4 Grant or award See Remarks acquired 126,087 shares (grant or award)
- 4 Grant or award Chief Development Officer acquired 185,605 shares (grant or award)
- 4 Open-market buy Director bought 4,323 shares at $3.48 ($15,025)
- 4 Open-market buy President and CEO bought 17,700 shares at $3.36 ($59,546)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award President and CEO acquired 250,000 shares (grant or award)
Page 4 of 12 · 223 filings